Recombinant protein · Agonist of insulin receptor (INSR) · developed by Novo Nordisk
ApprovedFDA, Sep 2015
1Registered trials
What is Degludec insulin?
Insulin degludec is a long-acting human insulin analog that lowers blood glucose by stimulating peripheral glucose uptake and inhibiting hepatic glucose production. It is used to improve glycemic control in diabetes mellitus. It is also combined with liraglutide, a GLP-1 receptor agonist, in one product.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
Insulin Degludec, Tresiba, Xultophy 100/3.6
Drug type
Recombinant protein
Targets
insulin receptor (INSR)
Mechanism
Agonist of insulin receptor (INSR)
Pathways
glucose uptake, hepatic glucose production inhibition, lipolysis inhibition, protein synthesis
Approved as Insulin Degludec, Tresiba, Xultophy 100/3.6 (September 25, 2015), BLA208583 · FDA label
✅ FDA-approved uses
Diabetes mellitus (Tresiba)
Diabetes mellitus (Insulin Degludec)
Type 2 diabetes mellitus (Xultophy 100/3.6)
From the indications section of the FDA label (version of Feb 22, 2024). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.